Exploring Research Collaboration on Pneumococcal Vaccine: Master of Public Health Program, Prodia the CRO and Minhai Beijing Biotechnology Ltd.

• By Admin
• Senin, 29 April 2024

The Master of Public Health (MPH) program received a delegation from Minhai Beijing Biotechnology Ltd. and Prodia the CRO to explore research collaboration on pneumococcal vaccine development on April 29, 2024. The Minhai team, led by Director Li Guifan, and the Prodia team, led by Dr. Ida Paulina, were welcomed by the Udayana team, led by a faculty member Dr. I Gusti Ayu Trisna Windiani, Sp.A (K). The discussion focused on plans and strategies for vaccine implementation in Bali, particularly in Denpasar. Dr. Trisna and her team have conducted several clinical trials on vaccines in the past, involving primary health care centers (Puskesmas) as study sites. Drawing from these experiences, thorough discussions regarding the study plan were conducted.

Regardless of whether the Udayana team secures this project, this initiative represents a tangible effort to seize better collaboration opportunities with international partners, aligning with the Vision and Mission of the MPH program, Faculty of Medicine, and Udayana University. The selection of the Udayana team as the proposed site by Prodia the CRO to Minhai reflects confidence in the Udayana team's performance in previous research endeavors, which undoubtedly need to be continuously maintained and improved.

Following discussions at the university, the exploration activities proceeded with visits to the planned study sites, namely Puskesmas Denpasar Selatan I and Puskesmas Denpasar Utara II, and subsequently to the Prodia Laboratory. This underscores the MPH program's excellent collaboration and coordination with the Health Department, primary health care centers, and private entities.

The team's enthusiasm is commendable!